Welcome to our dedicated page for Pfizer news (Ticker: PFE), a resource for investors and traders seeking the latest updates and insights on Pfizer stock.
The Pfizer Inc. (NYSE: PFE) news page on Stock Titan aggregates company announcements, clinical data readouts, financial updates and legal developments for one of the world’s major biopharmaceutical manufacturers. Pfizer’s news flow reflects its role in pharmaceutical preparation manufacturing, with frequent updates on prescription medicines, vaccines and late‑stage clinical programs.
Investors and observers can find detailed coverage of oncology trial results, such as Phase 3 data for BRAFTOVI (encorafenib) combinations in BRAF V600E‑mutant metastatic colorectal cancer, PADCEV (enfortumab vedotin) plus pembrolizumab in muscle‑invasive bladder cancer, and TUKYSA (tucatinib) in HER2‑positive metastatic breast cancer. These releases typically report on endpoints like objective response rate, progression‑free survival, event‑free survival and overall survival, along with safety profiles and plans for regulatory discussions.
Pfizer news also includes corporate and financial communications, such as earnings webcasts, performance reports, forward‑year revenue and adjusted EPS guidance, and dividend declarations. Recent releases describe full‑year revenue guidance ranges, expected contributions from COVID‑19 products, the impact of loss of exclusivity for certain medicines, and ongoing cost realignment efforts. Dividend announcements highlight Pfizer’s long record of consecutive quarterly cash dividends.
Another important category is business development and pipeline expansion. News items cover transactions like the acquisition of Metsera, which adds GLP‑1‑based obesity candidates, and an exclusive global collaboration and license agreement with YaoPharma for the small‑molecule GLP‑1 receptor agonist YP05002. These updates explain how Pfizer is building its cardiometabolic and obesity portfolio.
Regulatory, safety and legal topics also appear in the news stream, including multidistrict litigation related to Depo‑Provera and FDA label changes adding brain tumor warnings. By following this page, readers can monitor how scientific, financial and legal events shape Pfizer’s outlook and product portfolio over time.
Pfizer (NYSE: PFE) announced that the U.S. FDA approved PADCEV plus Keytruda as a perioperative (neoadjuvant then adjuvant) treatment for adult cisplatin-ineligible patients with muscle-invasive bladder cancer (MIBC) on November 21, 2025.
Approval was based on Phase 3 EV-303 (KEYNOTE-905) data showing 60% lower risk of recurrence/progression/death (EFS HR=0.40; p<0.0001) and a 50% lower risk of death (OS HR=0.50; p=0.0002) versus surgery alone; median EFS and OS are not reached for the combination. Grade ≥3 adverse events occurred in 71.3% of combination patients versus 45.9% for surgery alone.
Pfizer (NYSE: PFE) completed its acquisition of Metsera on November 13, 2025, buying all outstanding Metsera shares for $65.60 per share in cash and an enterprise value of approximately $7.0 billion.
The deal includes a contingent value right (CVR) of up to $20.65 per share tied to three clinical and regulatory milestones. Metsera is now a Pfizer subsidiary and its common stock will cease trading on NASDAQ. Key assets transferred include MET-097i (weekly/monthly GLP-1 RA entering Phase 3), MET-233i (monthly amylin analog in Phase 1), an oral GLP-1 RA in Phase 1, and preclinical hormone therapeutics.
Pfizer expects the transaction to be dilutive through 2030 and will update financial outlook with 2026 guidance later this year.
Pfizer (NYSE: PFE) will webcast a discussion with Dave Denton, CFO, at the Jefferies London Healthcare Conference on Wednesday, November 19, 2025 at 9:00 a.m. GMT.
Investors and the public can register and access the live webcast at www.pfizer.com/investors. A transcript and replay will be posted within 24 hours after the live event and will remain available for at least 90 days. Registration information is available beginning today on the investor website.
The webcast may include forward-looking statements; risk factors are available in Pfizer's Form 10-K for the year ended December 31, 2024 and subsequent SEC reports.
Summary not available.
Pfizer (NYSE: PFE) reported Q3 2025 revenues of $16.7B and raised and narrowed full-year 2025 adjusted diluted EPS guidance to $3.00–$3.15 while reaffirming revenue guidance of $61.0–$64.0B. Q3 adjusted diluted EPS was $0.87 and reported diluted EPS was $0.62. The company delivered ~$7.2B anticipated net cost-savings target by end of 2027 trajectory and invested $7.2B in internal R&D in the first nine months. The quarter saw operational growth in key brands (Eliquis +22% operationally) while COVID products declined.
Summary not available.
Summary not available.
Pfizer (NYSE: PFE) announced on October 31, 2025 that the U.S. Federal Trade Commission granted early termination of the waiting period under the Hart-Scott-Rodino Act for Pfizer’s pending acquisition of Metsera (NASDAQ: MTSR).
The early termination satisfies the HSR Act regulatory review requirements for the proposed acquisition, which had a waiting-period expiry date of November 7, 2025. The transaction remains pending other closing conditions.
Summary not available.
Pfizer (NYSE: PFE) and Astellas announced final Phase 3 EMBARK results showing that XTANDI plus leuprolide reduced the risk of death by 40.3% (HR 0.597; 95% CI 0.444-0.804; p=0.0006) versus leuprolide alone in men with non-metastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence.
The 8-year overall survival was 78.9% with XTANDI plus leuprolide vs 69.5% with leuprolide. Median follow-up was ~94 months. XTANDI monotherapy showed a numerical but not statistically significant OS improvement (HR 0.83; p=0.1867). Safety was consistent with prior analyses; common adverse events included hot flashes, fatigue and gynecomastia.